Table 2.
Characteristics of the patients and response to treatment options.
| Number of patient | Gender | Age, years | Weight, kg | Treatment prior to dupilumab |
Scores at dupilumab initiation |
Initial response to dupilumab (M3) | De novo or worsening of a HAND in patients with partial response to dupilumab (M3) | Treatment options | Response to the treatment options (M3) | Subsequent treatment with JAKi, mg/day | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MTX | Photo-therapy | CsA | SCORAD | DLQI | EASI | IGA | |||||||||
| 1 | m | 23 | 63 | 1 | na | na | na | 2 | PR | Combination of dupilumab with CsA | CR | ||||
| 2 | m | 31 | 65 | 1 | 33.1 | 9 | na | na | PR | yes | Combination of dupilumab with MTX | CR | |||
| 3 | m | 27 | 75 | 1 | 50.3 | 25 | na | 4 | PR | Combination of dupilumab with MTX | NR | upadacitinib 30 | |||
| 4 | m | 48 | 80 | 1 | 1 | 47 | 19 | na | 4 | NR | Combination of dupilumab with CsA | PR | |||
| 5 | m | 60 | 70 | 1 | 1 | 60 | 13 | na | na | NR | Combination of dupilumab with MTX | PR | upadacitinib 30 | ||
| 6 | m | 26 | 80 | 1 | 51.6 | 7 | na | na | PR | Increased dose of dupilumab | CR | ||||
| 7 | f | 48 | 95 | 1 | 56 | 23 | na | na | PR | yes | Combination of dupilumab with ITRA | NR | |||
| 8 | f | 33 | 64 | 1 | 1 | na | na | na | 3 | PR | Increased dose of dupilumab | CR | |||
| 9 | m | 57 | 59 | 1 | 1 | 67 | na | na | na | PR | Increased dose of dupilumab | CR | |||
| 10 | m | 38 | 95 | 1 | 18 | na | na | na | PR | Combination of dupilumab with CsA | CR | ||||
| 11 | m | 28 | 84 | 29.2 | na | na | na | PR | Combination of dupilumab with ITRA | NR | |||||
| 12 | m | 39 | 70 | 1 | 51 | 14 | 16 | 3 | PR | yes | Combination of dupilumab with ITRA | NR | |||
| 13 | f | 36 | 51 | 1 | 1 | 1 | 45 | 24 | 2.1 | 2 | PR | Combination of dupilumab with MTX | NR | ||
| 14 | m | 21 | 60 | 1 | 1 | 1 | 46 | 27 | na | 3 | PR | Increased dose of dupilumab | PR | ||
| 15 | f | 32 | 56 | 1 | na | 3 | 17.6 | 3 | PR | Increased dose of dupilumab | CR | ||||
| 16 | m | 51 | 83 | 1 | 1 | 26 | 3 | 14.7 | 2 | PR | yes | Combination of dupilumab with ITRA | CR | ||
| 17 | m | 30 | 63 | 1 | 1 | 1 | 94 | 30 | 49 | 4 | PR | Combination of dupilumab with CsA | CR | ||
| 18 | f | 39 | 93 | 1 | 1 | 55 | 25 | 19 | 4 | PR | Increased dose of dupilumab | CR | |||
| 19 | m | 34 | 85 | 1 | 1 | 50 | 23 | 11 | 3 | NR | Increased dose of dupilumab | PR | |||
| 20 | f | 27 | 53 | 1 | 63 | 22.8 | 3 | RP | Increased dose of dupilumab | NR | upadacitinib 30 | ||||
| 21 | f | 61 | 88 | 1 | 1 | 1 | 70 | 25 | 20 | 4 | RP | yes | Combination of dupilumab with ITRA | CR | |
| 22 | f | 26 | 53 | 1 | 1 | 47 | 20 | 17 | 4 | RP | Combination of dupilumab with CsA | PR | |||
| 23 | f | 44 | 55 | 1 | 1 | 38 | 25 | 12 | 3 | RP | yes | Combination of dupilumab with ITRA | CR | ||
| 24 | m | 36 | 95 | 1 | 1 | 1 | 55 | 26 | 18 | 4 | RP | Increased dose of dupilumab | NR | baracitinib 4 | |
| 25 | m | 26 | 63 | 1 | 1 | 30.5 | 5 | 5 | 2 | RP | yes | Combination of dupilumab with ITRA | PR | ||
| 26 | m | 40 | 70 | 1 | 1 | 26 | 6 | 4.5 | 2 | RP | Combination of dupilumab with MTX | CR | |||
| 27 | f | 24 | 63 | 1 | 72.5 | 21 | 25.2 | 4 | RP | Combination of dupilumab with MTX | CR | ||||
| 28 | f | 49 | 69 | 1 | 60 | 12 | 10.4 | 4 | RP | Combination of dupilumab with MTX | PR | ||||
| 29 | m | 26 | 62 | 1 | 1 | 1 | 71.5 | 14 | 16.4 | 4 | RP | yes | Combination of dupilumab with MTX | PR | |
| 30 | m | 34 | 88 | 1 | 1 | 1 | na | na | na | 4 | NR | Combination of dupilumab with MTX | NR | ||
| 31 | m | 32 | 79 | 1 | 1 | 68.3 | 4 | 36.3 | 3 | PR | Increased dose of dupilumab | CR | |||
| 32 | f | 22 | 65 | 1 | 42 | 8 | 29.6 | 3 | PR | Increased dose of dupilumab | NR | upadacitinib 30 | |||
| 33 | m | 22 | 78 | 1 | 1 | 38 | 3 | na | na | NR | Increased dose of dupilumab | NR | |||
| 34 | f | 35 | 90 | 1 | 1 | 48 | na | na | na | NR | Increased dose of dupilumab | NR | |||
| 35 | m | 42 | 69 | 1 | 1 | 1 | na | na | na | 3 | PR | Increased dose of dupilumab | CR | ||
| 36 | f | 45 | 78 | 1 | 1 | 1 | 82 | 16 | na | 3 | PR | Increased dose of dupilumab | NR | upadacitinib 30 | |
| 37 | m | 56 | 118 | 41 | 18 | na | 3 | PR | Increased dose of dupilumab | CR | |||||
| 38 | m | 19 | 46 | 1 | 64 | 8 | na | 3 | PR | Combination of dupilumab with MTX | CR | ||||
| 39 | m | 44 | 48 | 1 | 1 | 68 | 21 | na | 3 | PR | Combination of dupilumab with MTX | CR | |||
| 40 | m | 64 | 75 | 1 | 1 | 63 | 7 | na | 3 | PR | Combination of dupilumab with MTX | CR | |||
| 41 | f | 37 | 45 | 1 | 1 | 1 | 30 | 7 | na | 2 | PR | Combination of dupilumab with MTX | CR | upadacitinib 30 | |
| 42 | m | 21 | 62 | 1 | na | na | na | na | PR | yes | Combination of dupilumab with ITRA | PR | |||
| 43 | m | 51 | 67 | 1 | 1 | 76 | 29 | 34.4 | 4 | PR | Increased dose of dupilumab | PR | upadacitinib 30 | ||
| 44 | f | 29 | 66 | 1 | 1 | 1 | 69 | 5 | 18.5 | 4 | PR | Increased dose of dupilumab | NR | upadacitinib 30 | |
| 45 | f | 52 | 68 | 1 | 1 | 1 | 66 | na | 24 | 4 | PR | Increased dose of dupilumab | NR | upadacitinib 30 | |
| 46 | m | 21 | 50 | 1 | na | na | 22.5 | 4 | PR | Increased dose of dupilumab | NR | upadacitinib 30 | |||
| 47 | m | 31 | 80 | na | 29 | na | 4 | PR | Increased dose of dupilumab | CR | |||||
| 48 | f | 15 | 64 | 1 | 1 | na | na | na | 3 | PR | Combination of dupilumab with MTX | PR | |||
m male, f female, na data not available, CR complete or almost complete response, PR partial response, NR no response, CsA cyclosporin A, MTX methotrexate, ITRA itraconazole, M month, JAKi Janus Kinase inhibitors, HAND head and neck dermatitis, SCORAD scoring atopic dermatitis, EASI eczema area and severity index, IGA investigator's global assessment